Aditxt
Open
$0.21
Prev. Close
$0.21
High
$0.22
Low
$0.21
Market Snapshot
$15.17K
-0.0
-33454.44
$133.99K
26
Aditxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
emptyResult
Aditxt Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Richmond, Virginia and currently employs 26 full-time employees. The company went IPO on 2020-06-19. Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. The company develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. The company also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
Recently from Cashu
Aditxt Enhances Immune Health Innovations and Expands Focus to Precision Health Solutions
Aditxt Expands Focus on Immune and Precision Health Innovations Aditxt, Inc., a California-based social innovation platform, is making strides in the field of immune health through its subsidiaries, p…
Aditxt's Strategic Innovations in Health: Focus on Autoimmune and Cancer Detection Solutions
Aditxt's Strategic Expansion in Health Innovations Aditxt, Inc., a social innovation platform based in Mountain View, California, is poised to enhance its position in the health innovation sector thro…
Aditxt's Pearsanta Targets Cancer Diagnostics with Upcoming IPO for Innovative Solutions
Aditxt Paves the Way for Cancer Diagnostics Innovation Aditxt, Inc., a social innovation platform dedicated to advancing health technologies, is making significant strides in the realm of precision di…
Aditxt Pursues IPO for Pearsanta to Enhance Cancer Diagnostics and Health Innovations
Aditxt's Strategic Initiative to Amplify Cancer Diagnostics Through IPO Aditxt, Inc. takes a significant step towards enhancing its health innovation platform by authorizing its Board of Directors to…